FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
22 Octubre 2024 - 8:15AM
Business Wire
- Oncologic Drugs Advisory Committee (ODAC) determines risks
outweigh benefits in some cancers for frontline immune checkpoint
inhibitors, including blockbuster drugs such as Keytruda and
Opdivo, in patients with low PD-L1 expression
- Multikine has shown survival benefit and favorable safety
profile in a randomized controlled Phase 3 study of treatment naïve
resectable locally advanced head and neck cancer patients with low
PD-L1 expression
- Multikine has potential as a combination drug with current
checkpoint inhibitors such as Keytruda which is projected to be the
top selling drug in the world with $27 billion in 2024
sales
- To the Company’s knowledge, Multikine is the only
neoadjuvant immunotherapy that has shown overall survival benefit
in the low and negative PD-L1 head and neck cancer
population
CEL-SCI Corporation (NYSE American: CVM) today announced
the potential positive impact on the clinical development of its
immunotherapy Multikine® (Leukocyte Interleukin, Injection)*
resulting from a recent U.S. Food and Drug Administration (FDA)
Oncologic Drugs Advisory Committee (ODAC) meeting, a public
forum.
FDA advisory committees provide independent expert advice to the
FDA on the safety and effectiveness of new and marketed drugs and
help the agency make sound and informed decisions. Advisory
committees make non-binding recommendations to the FDA, which
generally follows the recommendations but is not legally bound to
do so.
The September 27, 2024 ODAC meeting evaluated the use of
checkpoint inhibitors on patients with various cancers. PD-L1 is
the biomarker most often used for patient selection for checkpoint
inhibitors, the most successful class of cancer drugs including
Keytruda and Opdivo. The FDA sought the ODAC’s opinion on the
following:
- adequacy of PD-L1 expression as a predictive biomarker for
patient selection in this patient population
- differing risk-benefit assessments in different subpopulations
defined by PD-L1 expression
- adequacy of the cumulative data to restrict the approvals of
immune checkpoint inhibitors based on PD-L1 expression
Following a thorough analysis of peer-reviewed published data,
the panel of experts on the ODAC voted 10-2 and 11–1 against the
risk-benefit profile for PD-L1 inhibitors in various cancers in two
separate votes. Most ODAC members expressed concerns about the lack
of benefit demonstrated for patients with low PD-L1 expression,
while some members pointed to evidence that the use of the immune
checkpoint inhibitors may add unnecessary toxicities for patients
while also increasing financial burdens on patients.
Checkpoint inhibitors were an estimated $48 billion global
market in 2023, with PD-L1 inhibitors representing 73% of the
market. Current labeling for approved checkpoint inhibitors in the
indications evaluated by the FDA’s ODAC include broad approvals for
all patients, regardless of PD-L1 expression.
“The FDA advisory committee’s findings and public statement on
the risk-benefit of checkpoint inhibitors based on PD-L1 expression
is potentially a turning point in cancer treatment, pointing to a
major treatment gap in low and negative PD-L1 patients. While the
approved blockbuster checkpoint inhibitors, including Keytruda
which is expected to be the biggest selling drug in 2024, work well
in high PD-L1 expressing patients, to our knowledge, Multikine is
the only immunotherapy that is targeted to and has shown survival
benefit in the low and negative PD-L1 population. CEL-SCI has
already identified in our prior study low PD-L1 expression as a
predictive biomarker, representing about 70% of head and neck
cancer patients, which will be used as a selection criterion for
our upcoming FDA confirmatory Registration Study of Multikine in
the treatment of treatment-naïve resectable locally advanced head
and neck cancer,” stated CEL-SCI CEO Geert Kersten.
“The FDA’s ODAC decision further supports our belief that
Multikine holds strong potential in treating patients across a
wider range of solid tumor cancer indications alone and in
combination regimens,” Kersten concluded.
About CEL-SCI Corporation
CEL-SCI believes that boosting a patient’s immune system while
it is still intact should provide the greatest possible impact on
survival. Multikine is designed to help the immune system "target"
the tumor at a time when the immune system is still relatively
intact and thereby thought to be better able to mount an attack on
the tumor.
Multikine (Leukocyte Interleukin, Injection), a true first-line
cancer therapy, has been dosed in over 740 patients and received
Orphan Drug designation from the FDA for neoadjuvant therapy in
patients with squamous cell carcinoma (cancer) of the head and
neck. Based on the very strong data from the completed randomized
controlled Phase 3 study, the FDA agreed to CEL-SCI’s target
patient selection criteria and gave the go-ahead to conduct a
small, focused, confirmatory Registration Study which will enroll
212 patients. CEL-SCI will enroll newly diagnosed locally advanced
primary head and neck cancer patients with no lymph node
involvement (determined via PET scan) and with low PD-L1 tumor
expression (determined via biopsy), representing over 100,000
patients annually.
The Company has operations in Vienna, Virginia, and near/in
Baltimore, Maryland.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. When used in this press release, the words "intends,"
"believes," "anticipated," "plans" and "expects," and similar
expressions, are intended to identify forward-looking statements.
Such statements are subject to risks and uncertainties that could
cause actual results to differ materially from those projected.
Factors that could cause or contribute to such differences include
an inability to duplicate the clinical results demonstrated in
clinical studies, timely development of any potential products that
can be shown to be safe and effective, receiving necessary
regulatory approvals, difficulties in manufacturing any of the
Company's potential products, inability to raise the necessary
capital and the risk factors set forth from time to time in
CEL-SCI's filings with the Securities and Exchange Commission,
including but not limited to its report on Form 10-K for the year
ended September 30, 2023. The Company undertakes no obligation to
publicly release the result of any revision to these
forward-looking statements which may be made to reflect the events
or circumstances after the date hereof or to reflect the occurrence
of unanticipated events.
* Multikine (Leukocyte Interleukin, Injection) is the trademark
that CEL-SCI has registered for this investigational therapy. This
proprietary name is subject to FDA review in connection with the
Company's future anticipated regulatory submission for approval.
Multikine has not been licensed or approved for sale, barter or
exchange by the FDA or any other regulatory agency. Similarly, its
safety or efficacy has not been established for any use.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241021000924/en/
Gavin de Windt CEL-SCI Corporation (703) 506-9460
Cel Sci (AMEX:CVM)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Cel Sci (AMEX:CVM)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024